Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY ) 15.32 +0.12 (+0.79%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about ARS Pharmaceuticals, Inc. - Common Stock < Previous 1 2 Next > ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting October 24, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis September 23, 2024 Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference September 10, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) September 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis September 04, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) August 26, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis August 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference August 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results August 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) June 28, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results May 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand April 30, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) April 03, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day March 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 March 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study February 26, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024 February 22, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter February 20, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting February 05, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates November 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis November 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm October 26, 2023 Via ACCESSWIRE NASDAQ:SPRY Investor Notice: Investigation over Potential Securities Laws Violations by ARS Pharmaceuticals, Inc. October 11, 2023 San Diego, CA -- (SBWIRE) -- 10/11/2023 -- ARS Pharmaceuticals, Inc. is under investigation on over potential securities laws violations in connection with certain financial statements. Via SBWire ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray) October 06, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology October 03, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study September 19, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates August 10, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis June 20, 2023 Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results May 15, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm May 12, 2023 From The Schall Law Firm Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
